Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.68 |
| ▸ | CTSK | P43235 | 9/20 | 0.68 |
| ▸ | ASPH | Q12797 | 2/20 | 0.50 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 10/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595483 | 0.87 | CTSS (0.69) | CTSSCTSKCTSL | |
| SCHEMBL3587063 | 0.83 | CTSS (0.57) | CTSSCTSKCTSL | |
| SCHEMBL3589178 | 0.74 | CTSS (0.58) | CTSSCTSKCTSL | |
| SCHEMBL22261160 | 0.71 | JAK3 (0.55) | CTSSCTSKASPHKDM8KDM4E | |
| SCHEMBL25421683 | 0.70 | JAK3 (0.68) | JAK2JAK1JAK3 | |
| SCHEMBL10172449 | 0.70 | CHEK1 (0.66) | ASPHKDM8KDM4ERIOX2 | |
| SCHEMBL22261420 | 0.69 | JAK3 (0.54) | CTSSCTSKASPHKDM8KDM4E | |
| SCHEMBL23620374 | 0.69 | JAK3 (0.47) | ASPHKDM8KDM4ERIOX2KDM4C | |
| SCHEMBL30479327 | 0.69 | JAK3 (0.47) | ASPHKDM8KDM4ERIOX2KDM4C | |
| SCHEMBL3586485 | 0.69 | CTSS (0.48) | CTSSCTSKCTSLJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| EP-1781623-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | CTSS 1/4885CTSK 8/4885ASPH 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.